This webcast originally aired as a
live webinar sponsored by AACC on March 11, 2014. When the results of the
Women's Health Initiative (WHI) Estrogen Plus Progestin study demonstrated that
menopausal hormone therapy (HT) did not decrease cardiovascular risk as expected
and was associated with an increased risk of developing breast cancer,
clinicians stopped prescribing it routinely to women undergoing menopause.
However, HT is still prescribed to manage the symptoms of menopause, and recent
studies have shown that many newly menopausal women have a favorable
benefits:risk profile on HT. The key is to apply risk-stratification strategies
and personalization of care to identify appropriate candidates for treatment and
to avoid HT in women likely to have adverse events. View this program and learn
what recent data are telling us about the relationship between HT and CVD risk;
which women can benefit most from HT and which women should avoid HT; what role
labs can play in helping clinicians assess CVD risk in women considering HT; and
why a personalized approach to the prediction of risk for CVD and other
events while on HT makes sense.